Condition: Myelodysplastic Syndromes (MDS) · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The primary objective of this study is to describe the response to treatment with biosimilar EPO alpha in MDS patients who had already been treated with "originator" EPO alpha and were responsive, and in patients who started treatment with biosimilar EPO alpha
This description comes directly from the study's public registry record.
Stefania Paolini, MD · +390512143680 · stefania.paolini@unibo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliera -Universitaria di Bologna | Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06764511